Compare Regeneron Pharmaceuticals Inc (REGN) vs Walmart Stores Inc (WMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Walmart Stores Inc — how do they compare? Regeneron Pharmaceuticals Inc trades at $807.6 (market cap $83.43B), while Walmart Stores Inc trades at $106.17 (market cap $841.37B). The key difference: Walmart Stores Inc is far larger — about 10.1× Regeneron Pharmaceuticals Inc's market cap, and Walmart Stores Inc pays the higher dividend (0.93%). Which is the better fit depends on your goals.
| REGN | WMT | |
|---|---|---|
Market Cap | $83.43B | $841.37B |
Sector | Health | Consumer Staples |
52-Week High | $852.03 | $134.20 |
52-Week Low | $555.51 | $100.41 |
Enterprise Value | $78.14B | $903.60B |
Dividend Yield | 0.46% | 0.93% |
Volume | — | 5,675,288 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
Walmart (WMT) trades at $105.83, down 1.22% on the day, amid a bearish technical signal but strong fundamental performance. The company has beaten EPS estimates for three consecutive quarters, with revenue reaching $680.99 billion in 2025 and net income margin improving to 2.85%. Analyst consensus is strongly bullish with a $130.69 price target, though technical indicators show near-term resistance around $107.
The outlook remains positive given consistent earnings beats, expanding profit margins, and strategic initiatives in delivery and AI. Key risks include competitive pressure from Amazon, which recently surpassed Walmart in revenue, and potential margin compression from increased investment. The stock offers a compelling long-term growth story supported by operational efficiency and market dominance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Walmart Stores Inc
Walmart Inc. operates discount stores, supercenters, and neighborhood markets. The Company offers merchandise such as apparel, house wares, small appliances, electronics, musical instruments, books, home improvement, shoes, jewelry, toddler, games, household essentials, pets, pharmaceutical products, party supplies, and automotive tools. Walmart serves customers worldwide.
Read more on WMT →
